The oral contraceptive pill for lung cancer from Amgen Inc. has been approved by the U.S. Food and Drug Administration. and adding a new potential blockbuster to the biotech giant’s elixir.
The drug, called Lumakras, was approved Friday to treat some lung cancer patients with a specific genetic mutation who have already tried other therapies.
A mutation called KRAS is the most common type of cancer. But researchers have struggled for years to find a drug that could treat it. which this mutation is considered “Can’t resist”
The Food and Drug Administration (FDA) approval, which has accelerated through clinical trials since its first encouraging results in 2019, testifies to Amgen’s drug discovery capabilities. analyst said
The company̵7;s drug launch will be closely watched by investors and analysts who want to see Amgen offset lower revenue from older products, including rheumatoid drug Enbrel.